tradingkey.logo

Caris Life Sciences Inc

CAI
27.940USD
+0.080+0.29%
收盤 12/19, 16:00美東報價延遲15分鐘
7.88B總市值
虧損本益比TTM

Caris Life Sciences Inc

27.940
+0.080+0.29%

關於 Caris Life Sciences Inc 公司

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Caris Life Sciences Inc簡介

公司代碼CAI
公司名稱Caris Life Sciences Inc
上市日期Jun 18, 2025
CEOHalbert (David Dean)
員工數量- -
證券類型Ordinary Share
年結日Jun 18
公司地址750 W. John Carpenter Freeway
城市IRVING
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編75039
電話18667718946
網址https://www.carislifesciences.com/
公司代碼CAI
上市日期Jun 18, 2025
CEOHalbert (David Dean)

Caris Life Sciences Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Vice Chairman of the Board
Vice Chairman of the Board
511.70K
-2.76%
Mr. Luke Power
Mr. Luke Power
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
99.57K
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Independent Director
Independent Director
16.13K
--
Mr. Nathan Burns
Mr. Nathan Burns
Independent Director
Independent Director
--
--
Mr. Vijay Mohan
Mr. Vijay Mohan
Independent Director
Independent Director
--
--
Mr. Danny Phillips
Mr. Danny Phillips
Independent Director
Independent Director
--
--
Dr. Lloyd B. Minor, M.D.
Dr. Lloyd B. Minor, M.D.
Independent Director
Independent Director
--
--
Mr. Peter M. Castleman
Mr. Peter M. Castleman
Lead Independent Director
Lead Independent Director
--
--
J. Russel Denton
J. Russel Denton
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Dr. Jeffrey L. (Jeff) Vacirca, M.D.
Dr. Jeffrey L. (Jeff) Vacirca, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Vice Chairman of the Board
Vice Chairman of the Board
511.70K
-2.76%
Mr. Luke Power
Mr. Luke Power
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
99.57K
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Independent Director
Independent Director
16.13K
--
Mr. Nathan Burns
Mr. Nathan Burns
Independent Director
Independent Director
--
--
Mr. Vijay Mohan
Mr. Vijay Mohan
Independent Director
Independent Director
--
--
Mr. Danny Phillips
Mr. Danny Phillips
Independent Director
Independent Director
--
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
由於公司未披露,未能獲取相關數據
地區USD
名稱
營收
佔比
United States
178.18M
98.22%
International
3.22M
1.78%
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Halbert (David D)
43.51%
Sixth Street Partners, LLC
8.64%
J.H. Whitney Capital Partners, LLC
7.18%
Castleman Peter M
3.68%
Coatue Management, L.L.C.
3.59%
其他
33.40%
持股股東
持股股東
佔比
Halbert (David D)
43.51%
Sixth Street Partners, LLC
8.64%
J.H. Whitney Capital Partners, LLC
7.18%
Castleman Peter M
3.68%
Coatue Management, L.L.C.
3.59%
其他
33.40%
股東類型
持股股東
佔比
Individual Investor
48.47%
Investment Advisor
20.21%
Hedge Fund
11.05%
Private Equity
10.52%
Investment Advisor/Hedge Fund
4.85%
Pension Fund
0.53%
Research Firm
0.29%
Sovereign Wealth Fund
0.13%
Bank and Trust
0.08%
其他
3.86%

機構持股

更新時間: 7月2日 週三
更新時間: 7月2日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
172
130.04M
46.09%
+127.36M
2025Q2
45
192.42M
69.23%
+189.87M
2025Q1
3
2.55M
0.92%
+2.55M

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Halbert (David D)
122.76M
43.65%
-141.96K
-0.12%
Aug 11, 2025
Sixth Street Partners, LLC
24.39M
8.67%
+24.39M
--
Jun 30, 2025
J.H. Whitney Capital Partners, LLC
20.26M
7.2%
+20.26M
--
Jun 30, 2025
Castleman Peter M
10.37M
3.69%
+10.34M
+32049.87%
Jun 18, 2025
Coatue Management, L.L.C.
10.14M
3.61%
+10.14M
--
Jun 30, 2025
Fidelity Management & Research Company LLC
8.61M
3.06%
+8.61M
--
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
7.30M
2.6%
+7.30M
--
Jun 30, 2025
Braidwell LP
7.32M
2.6%
+7.32M
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
6.76M
2.4%
+6.76M
--
Jun 30, 2025
Silver Lake Partners
5.29M
1.88%
+5.29M
--
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
ARK Genomic Revolution ETF
0.67%
Texas Capital Texas Small Cap Equity Index ETF
0.52%
Renaissance IPO ETF
0.43%
RiverNorth Patriot ETF
0.3%
Franklin Genomic Advancements ETF
0.29%
Invesco Russell 1000 Equal Weight ETF
0.08%
Inspire 500 ETF
0.07%
T Rowe Price Small-Mid Cap ETF
0.05%
Texas Capital Texas Equity Index ETF
0.04%
Fidelity Nasdaq Composite Index ETF
0.02%
查看更多
ARK Genomic Revolution ETF
佔比0.67%
Texas Capital Texas Small Cap Equity Index ETF
佔比0.52%
Renaissance IPO ETF
佔比0.43%
RiverNorth Patriot ETF
佔比0.3%
Franklin Genomic Advancements ETF
佔比0.29%
Invesco Russell 1000 Equal Weight ETF
佔比0.08%
Inspire 500 ETF
佔比0.07%
T Rowe Price Small-Mid Cap ETF
佔比0.05%
Texas Capital Texas Equity Index ETF
佔比0.04%
Fidelity Nasdaq Composite Index ETF
佔比0.02%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Caris Life Sciences Inc的前五大股東是誰?

Caris Life Sciences Inc的前五大股東如下:
Halbert (David D)
持有股份:122.76M
佔總股份比例:43.65%。
Sixth Street Partners, LLC
持有股份:24.39M
佔總股份比例:8.67%。
J.H. Whitney Capital Partners, LLC
持有股份:20.26M
佔總股份比例:7.20%。
Castleman Peter M
持有股份:10.37M
佔總股份比例:3.69%。
Coatue Management, L.L.C.
持有股份:10.14M
佔總股份比例:3.61%。

Caris Life Sciences Inc的前三大股東類型是什麼?

Caris Life Sciences Inc 的前三大股東類型分別是:
Halbert (David D)
Sixth Street Partners, LLC
J.H. Whitney Capital Partners, LLC

有多少機構持有Caris Life Sciences Inc(CAI)的股份?

截至2025Q3,共有172家機構持有Caris Life Sciences Inc的股份,合計持有的股份價值約為130.04M,占公司總股份的46.09% 。與2025Q2相比,機構持股有所增加,增幅為-23.14%。

哪個業務部門對Caris Life Sciences Inc的收入貢獻最大?

在FY2025Q2,--業務部門對Caris Life Sciences Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI